摘要
目的探讨培美曲塞联合奈达铂化疗在晚期肺腺癌患者治疗中的应用效果。方法选取2014年2月~2015年2月我院肿瘤内科收治的60例晚期肺腺癌患者作为研究对象,随机分为治疗组与对照组,每组各30例。对照组采用吉西他滨联合奈达铂化疗,治疗组采用培美曲塞联合奈达铂化疗,比较两组患者的治疗总有效率、治疗前后血清肿瘤标志物水平及不良反应发生情况,门诊或电话随访4~24个月,记录两组患者的总生存时间。结果治疗组患者的治疗总有效率为63.33%,高于对照组的36.67%(P<0.05);治疗组患者治疗后的血清癌胚抗原(CEA)、糖分解烯醇酶(NSE)、糖链抗原50(CA50)、糖类抗原199(CA199)水平均低于对照组(P<0.05);治疗组患者脱发、皮疹、白细胞减少、中性粒细胞减少、血小板减少、肝肾功能损伤、恶心呕吐的发生率均低于对照组(P<0.05);治疗组患者的总生存时间为(18.56±4.67)个月,长于对照组的(14.29±4.72)个月(P<0.05)。结论培美曲塞联合奈达铂化疗治疗晚期肺腺癌的效果显著,可以有效改善血清肿瘤标志物水平,延长生存时间。
Objective To explore the application effects of Pemetrexed combined with Nedaplatin chemotherapy in the treatment of patients with advanced lung adenocarcinoma.Methods A total of 60 patients with advanced lung adenocarcinoma treated in department of medical oncology of our hospital from February 2014 to February 2015 were selected as the subjects,and randomly divided into treatment group and control group,with 30 cases in each group.The control group was treated with Gemcitabine combined with Nedaplatin chemotherapy,and the treatment group was given Pemetrexed combined with Nedaplatin chemotherapy.The effective rate of treatment,serum tumor marker levels before and after treatment and occurrence of adverse reactions were compared between the two groups.Patients were given 4 to 24 months of outpatient or telephone follow-up,and the overall survival time was recorded of the two groups.Results The total effective rate of treatment in treatment group (63.33%) was higher than that in control group (36.67%)(P<0.05).The levels of serum carcinoembryonic antigen (CEA),neuron-specific enolase (NSE),carbohydrate antigen 50 (CA50) and carbohydrate antigen (CA199) in treatment group were lower than those in control group after treatment (P<0.05).The incidence rates of alopecia,rash,leukopenia,neutropenia,thrombocytopenia,liver and kidney function damage and nausea and vomiting in treatment group were lower than those in control group (P<0.05).The overall survival time in treatment group was (18.56±4.67) months,which was longer than that in control group ([14.29±4.72]months)(P<0.05).Conclusion Pemetrexed combined with Nedaplatin chemotherapy has significant efficacy in the treatment of advanced lung adenocarcinoma,and it can effectively improve serum tumor markers levels and prolong survival time.
作者
杨锭洪
林长裕
黄晓龙
YANG Ding-hong;LIN Chang-yu;HUANG Xiao-long(Department of Medical Oncology,Puning People's Hospital,Guangdong Province,Puning 515300,China)
出处
《中国当代医药》
2019年第17期61-64,共4页
China Modern Medicine
关键词
肺腺癌化疗
培美曲塞
吉西他滨
奈达铂
Lung adenocarcinoma chemotherapy
Pemetrexed
Gemcitabine
Nedaplatin
